Virtu KCG Holdings’s Arbutus Biopharma ABUS Stock Holding History

Virtu KCG Holdings’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$45K	Buy	+12,433	New	+$42.8K	﹤0.01%	2613
2017 Q1	–	Sell	-23,700	Closed	-$58K	–	3072
2016 Q4	$58K	Sell	23,700 -5,857	-20%	-$17K	﹤0.01%	3057
2016 Q3	$102K	Buy	+29,557	New	+$115K	﹤0.01%	2630
2014 Q4	–	Sell	-44,629	Closed	-$942K	–	3699
2014 Q3	$942K	Buy	44,629 +19,416	+77%	+$317K	0.02%	1014
2014 Q2	$329K	Buy	25,213 +5,561	+28%	+$78.8K	0.01%	2435
2014 Q1	$422K	Sell	19,652 -8,568	-30%	-$154K	0.01%	2148
2013 Q4	$223K	Buy	28,220 +14,968	+113%	+$125K	﹤0.01%	2982
2013 Q3	$92K	Buy	+13,252	New	+$73K	﹤0.01%	3391

Other funds holding ABUS

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

KPF

K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Virtu KCG Holdings's ABUS Position: Q2 2017 in Review

Virtu KCG Holdings opened a new position in Arbutus Biopharma (ABUS) in Q2 2017: 12,433 shares worth $45K. The stake represents ﹤0.01% of the portfolio and ranks #2613 among its holdings. This is a return to the name: Virtu KCG Holdings previously reported a position in ABUS as recently as Q4 2016.

Virtu KCG Holdings first reported a position in ABUS in Q3 2013 and has held it in 8 quarters since. The position peaked at $942K in Q3 2014. 50 funds tracked by Wall St. Rank hold ABUS as of Q2 2017.

Virtu KCG Holdings held 12,433 shares of Arbutus Biopharma worth $45K as of Q2 2017.
Arbutus Biopharma was a new Virtu KCG Holdings position in Q2 2017.
Arbutus Biopharma made up ﹤0.01% of Virtu KCG Holdings's portfolio in Q2 2017, its #2613 holding.
Virtu KCG Holdings first reported a position in Arbutus Biopharma in Q3 2013 and has held it in 8 quarters since.
Virtu KCG Holdings's Arbutus Biopharma position peaked at $942K in Q3 2014.
50 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.